Initiative for Development of Novel Biomarkers in Immune Neuropathies

Initiative for Development of Novel Biomarkers in Immune Neuropathies - IDOBIN

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00010596

Enrollment

100

Registered

2016-06-07

Start date

2016-07-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Inflammatory Demyelinating Polyneuropathy G61.8

Interventions

Group 1: Obtaining serum and PBMC samples during the study for the determination of autoantibodies and biomarkers. The blood collection will be performed in total for six times (at 0, 3, 6, 9, 12, 24

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Fulfil the diagnostic criteria for CIDP of the Joint Task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. 2. IVIG therapy.

Exclusion criteria

Exclusion criteria: 1. Below the age of 18. 2. Pregnancy.

Design outcomes

Primary

Measure	Time frame
Identification of clinical parameters, autoantibodies and biomarkers to predict the disease course and outcome of chronic inflammatory demyelinating polyneuropathy in (CIDP) as quick as possible and with maximum safety.	—

Countries

Germany, India, Norway

Contacts

Public ContactHelmar Lehmann

Neurologie, Universitätsklinik Kön

helmar.lehmann@uk-koeln.de+49 221 478-87091

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026